| Document Date: 2014-11-03 11:26:21
Open Document File Size: 25,12 KBShare Result on Facebook
City Osaka / London / / Company Shionogi Inc. / ViiV / Pfizer / GlaxoSmithKline / ABC / HIV/AIDS / Shionogi & Co. Ltd. / Shionogi-ViiV Healthcare LLC / Healthcare ViiV Healthcare / Japan Shionogi & Co. / / Country United Kingdom / / Event FDA Phase / / IndustryTerm in-line products / pharmaceuticals / healthcare / pharmaceutical / with respect to product / / MedicalCondition cancer / HIV / allergy / Metabolic Syndrome / AIDS / Infectious Diseases / / Organization Federal Trade Commission / / Person Sapan Shah / John Pottage / David Mawdsley Sally Ferguson Gary / Rebecca Hunt Claire Brough / Tom Curry Jen Hill Baxter / Marc Meachem / / / Position Medical Officer / ViiV Healthcare / Analyst / forward / Private / President & CEO / Chief / / Product GSK1265744 / Investigational Once / GSK1349572 / SPRING-2 / / Technology pharmacokinetics / / URL www.shionogi.co.jp / www.shionogi-inc.com / www.viivhealthcare.com / /
SocialTag |
Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)